Effect of cytogenin, a novel immunomodulator, on streptozotocin-induced diabetes in mice
Related Experiment Video
Updated: Aug 18, 2026
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Hiroyuki Kumagai1, Kuniko Wakazono, Naoki Agata
1Numazu Bio-Medical Research Institute, Microbial Chemistry Research Foundation, 18-24 Miyamoto, Numazu, Shizuoka 410-0301, Japan.
Abstract:
The anti-diabetic effect of cytogenin was examined using streptozotocin-induced diabetes in mice. Cytogenin suppressed not only the increase of plasma glucose level but also the body weight reduction in diabetic mice. Histological examination of the pancreas taken from diabetic mice given cytogenin showed that cytogenin decreased the number of macrophages infiltrated into islet of pancreas. Further, cytogenin suppressed the nitric oxide generation by macrophages treated with lipopolysaccharide through decreasing of inducible nitric oxide synthase expression. Cytogenin suppressed interleukin-6 expression by macrophage treated with LPS, suggesting that the anti-diabetic activity of cytogenin might be partly attributed to the suppressive activity against nitric oxide generation.
Insights
Cytogenin demonstrates anti-diabetic effects by lowering plasma glucose and preventing weight loss in diabetic mice. It reduces pancreatic inflammation and nitric oxide generation, suggesting therapeutic potential for diabetes management.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Diabetes mellitus is a significant global health concern characterized by hyperglycemia.
- Inflammation, particularly involving macrophages in pancreatic islets, plays a crucial role in diabetes pathogenesis.
- Nitric oxide (NO) and interleukin-6 (IL-6) are key inflammatory mediators implicated in diabetes.
Purpose of the Study:
- To investigate the anti-diabetic effects of cytogenin.
- To elucidate the mechanisms underlying cytogenin's action in a mouse model of diabetes.
Main Methods:
- Streptozotocin-induced diabetes model in mice.
- Assessment of plasma glucose levels and body weight.
- Histological examination of pancreatic islets.
- Evaluation of macrophage infiltration, nitric oxide generation, inducible nitric oxide synthase (iNOS) expression, and IL-6 expression in macrophages.
Main Results:
- Cytogenin significantly suppressed the increase in plasma glucose levels and prevented body weight reduction in diabetic mice.
- Histological analysis revealed decreased macrophage infiltration into pancreatic islets of cytogenin-treated mice.
- Cytogenin inhibited lipopolysaccharide (LPS)-induced nitric oxide generation by macrophages by downregulating iNOS expression.
- Cytogenin suppressed IL-6 expression in LPS-treated macrophages.
Conclusions:
- Cytogenin exhibits significant anti-diabetic properties in a streptozotocin-induced mouse model.
- The therapeutic effects of cytogenin may be attributed to its ability to reduce pancreatic inflammation and suppress macrophage-derived nitric oxide and IL-6 production.
- Cytogenin represents a potential therapeutic agent for managing diabetes, warranting further investigation.
